Claims for Patent: 8,507,534

Summary for Patent: 8,507,534

Title:	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
Abstract:	The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-- methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.
Inventor(s):	Keshavarz-Shokri; Ali (San Diego, CA), Zhang; Beili (San Diego, CA), Krawiec; Mariusz (Marlborough, MA)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:	12/327,902
Patent Claims:	1. 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)- -3-methylpyridin-2-yl)benzoic acid characterized as Form I. 2. Form I of claim 1, wherein the Form I is characterized by one or more peaks at 15.2 to 15.6 degrees, 16.1 to 16.5 degrees, and 14.3 to 14.7 degrees in an X-ray powder diffraction obtained using Cu K alpha radiation. 3. Form I of claim 2, wherein the Form I is characterized by one or more peaks at 15.4, 16.3, and 14.5 degrees. 4. Form I of claim 2, wherein the Form I is further characterized by a peak at 14.6 to 15.0 degrees. 5. Form I of claim 4, wherein the Form I is further characterized by a peak at 14.8 degrees. 6. Form I of claim 4, wherein the Form I is further characterized by a peak at 17.6 to 18.0 degrees. 7. Form I of claim 6, wherein the Form I is further characterized by a peak at 17.8 degrees. 8. Form I of claim 6, wherein the Form I is further characterized by a peak at 16.4 to 16.8 degrees. 9. Form I of claim 8, wherein the Form I is further characterized by a peak at 16.4 to 16.8 degrees. 10. Form I of claim 9, wherein the Form I is further characterized by a peak at 16.6 degrees. 11. Form I of claim 9, wherein the Form I is further characterized by a peak at 7.6 to 8.0 degrees. 12. Form I of claim 11, wherein the Form I is further characterized by a peak at 7.8 degrees. 13. Form I of claim 11, wherein the Form I is further characterized by a peak at 25.8 to 26.2 degrees. 14. Form I of claim 13, wherein the Form I is further characterized by a peak at 26.0 degrees. 15. Form I of claim 13, wherein the Form I is further characterized by a peak at 21.4 to 21.8 degrees. 16. Form I of claim 15, wherein the Form I is further characterized by a peak at 21.6 degrees. 17. Form I of claim 15, wherein the Form I is further characterized by a peak at 23.1 to 23.5 degrees. 18. Form I of claim 17, wherein the Form I is further characterized by a peak at 23.3 degrees. 19. Form I of claim 1, wherein the Form I is characterized by a diffraction pattern substantially similar to that of FIG. 1. 20. Form I of claim 1, wherein the Form I is characterized by a diffraction pattern substantially similar to that of FIG. 2. 21. Form I of claim 1, wherein the particle size distribution of D90 is about 82 .mu.m or less. 22. Form I of claim 1, wherein the particle size distribution of D50 is about 30 .mu.m or less. 23. A pharmaceutical composition comprising Form I of claim 1, and a pharmaceutically acceptable carrier.